DVAX Dynavax Technologies Corporation

5.69
-0.01  -0%
Previous Close 5.7
Open 5.78
Price To Book 12.11
Market Cap 477,192,527
Shares 83,865,119
Volume 1,145,538
Short Ratio
Av. Daily Volume 1,113,341
Stock charts supplied by TradingView

NewsSee all news

  1. Dynavax Announces Partnership with Albertsons Companies' Pharmacies to Offer HEPLISAV-B® Hepatitis B Vaccine to Patients Nationwide

    - Partnership at 1,700 pharmacies nationwide with special focus on people living with diabetes- People living with diabetes are two times more likely to become infected with hepatitis B virus and up to four times as

  2. Dynavax Announces HEPLISAV-B Post-Marketing Requirement Interim Report Completed

    EMERYVILLE, Calif. , Dec. 03, 2019 (GLOBE NEWSWIRE) -- Dynavax Technologies Corporation (NASDAQ:DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, today announced that it has

  3. Dynavax to Present at the Stifel 2019 Healthcare Conference

    EMERYVILLE, Calif., Nov. 07, 2019 (GLOBE NEWSWIRE) -- Dynavax Technologies Corporation (NASDAQ:DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, today announced that Ryan

  4. Dynavax Announces Third Quarter 2019 Financial Results

    Third quarter 2019 HEPLISAV-B® net product revenue of $10.2 millionRaising revenue expectation range to $34-$36 million for full year 2019Conference call to be held today at 4:30 p.m. ET/1:30 p.m. PT EMERYVILLE, Calif.,

  5. Dynavax to Present at the 2019 Cantor Global Healthcare Conference

    BERKELEY, Calif., Sept. 30, 2019 (GLOBE NEWSWIRE) -- Dynavax Technologies Corporation (NASDAQ:DVAX), today announced that Ryan Spencer, Senior Vice President, Commercial, and Interim Co-President, will present at the

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Announced May 23, 2019 that it will discontinue investment in this program.
SD-101 + Pembrolizumab
Melanoma and head and neck squamous cell carcinoma (HNSCC)
CRL February 25, 2013 and November 14, 2016. Advisory Committee Meeting July 28, 2017 voted 21 -1 in favor of recommending approval. Final approval announced November 9, 2017.
HEPLISAV-B
Hepatitis B
Phase 2a trial did not meet primary endpoint - November 29, 2018.
AZD1419
Asthma
Announced May 23, 2019 that it will discontinue investment in this program.
DV281
Non-small Cell Lung Cancer (NSCLC)
Phase 1 commencement of enrolment announced May 2, 2019.
HEPLISAV-B
End Stage Renal Disease on Dialysis

Latest News

  1. Dynavax Announces Partnership with Albertsons Companies' Pharmacies to Offer HEPLISAV-B® Hepatitis B Vaccine to Patients Nationwide

    - Partnership at 1,700 pharmacies nationwide with special focus on people living with diabetes- People living with diabetes are two times more likely to become infected with hepatitis B virus and up to four times as

  2. Dynavax Announces HEPLISAV-B Post-Marketing Requirement Interim Report Completed

    EMERYVILLE, Calif. , Dec. 03, 2019 (GLOBE NEWSWIRE) -- Dynavax Technologies Corporation (NASDAQ:DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, today announced that it has

  3. Dynavax to Present at the Stifel 2019 Healthcare Conference

    EMERYVILLE, Calif., Nov. 07, 2019 (GLOBE NEWSWIRE) -- Dynavax Technologies Corporation (NASDAQ:DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, today announced that Ryan

  4. Dynavax Announces Third Quarter 2019 Financial Results

    Third quarter 2019 HEPLISAV-B® net product revenue of $10.2 millionRaising revenue expectation range to $34-$36 million for full year 2019Conference call to be held today at 4:30 p.m. ET/1:30 p.m. PT EMERYVILLE, Calif.,

  5. Dynavax to Present at the 2019 Cantor Global Healthcare Conference

    BERKELEY, Calif., Sept. 30, 2019 (GLOBE NEWSWIRE) -- Dynavax Technologies Corporation (NASDAQ:DVAX), today announced that Ryan Spencer, Senior Vice President, Commercial, and Interim Co-President, will present at the